The biopharmaceutical company LEADS BIOLABS-B (ASX: 09887) has announced that six of its latest research findings have been accepted for presentation at the 2026 European Society for Medical Oncology Annual Congress, a premier global oncology event.
Among the six selected studies, two have been chosen for the highest-tier oral presentation format, known as the Proffered Paper session, while four will be presented as poster exhibits. The research spans several therapeutic areas, including extrapulmonary neuroendocrine carcinoma, biliary tract cancer, and relapsed or refractory multiple myeloma.
Furthermore, the company has been granted a Late-Breaking Abstract status, with the full LBA submission scheduled for September 2026. The ESMO congress is scheduled to take place from October 23 to 27, 2026, in Madrid, Spain.
The Proffered Paper oral presentations are reserved by the ESMO congress for research deemed to have the most significant clinical impact and scientific innovation. The LBA category is specifically designed for the latest clinical research considered potentially practice-changing.
The selection of multiple studies for presentation reflects the international academic community's recognition of the quality of the company's clinical data and the value of its development pipeline. It also underscores the firm's continued innovation and robust pipeline advancement in the field of cancer immunotherapy.
Complete data from the accepted studies will be released online with the ESMO abstracts and during the congress proceedings.
Previously, the company also announced that a study on its candidate for first-line non-small cell lung cancer treatment has been selected for an oral presentation at the World Conference on Lung Cancer in September 2026. The full abstract for that presentation is expected to be published on the WCLC official website on August 19, 2026.
Comments